Pfizer Inc. (PFE)
EU regulator recommends use of Pfizer's gene therapy for rare bleeding disorder
The European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding disorder called hemophilia B, which typically requires regular infusions of a blood-clotting protein, the regulator said on Friday.
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Pfizer's dividend yield is rising as the stock price is falling.
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2 Beaten-Down Dividend Stocks Near 52-Week Lows. Should You Buy the Dips?
Investors looking for dividend stocks have probably noticed Pfizer and Walgreens Boots Alliance offer above-average yields. Walgreens Boots Alliance stock is under pressure after shutting down an initiative that would have made it more than just a retail pharmacy chain.
Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe?
A monthly chart of PFE using Worden's TC2000 Gold shows the stock oversold on a monthly basis. A stock with a 5.8-6% dividend yield in today's market immediately draws attention. Is the dividend sustainable, and will the pharma giant be able to sustain the current $0.42 per quarter ($1.68 per year) dividend pace and also continue to boost that dividend at a $0.04 per year (one penny per quarter) rate?
Pfizer: Turning The Corner (Rating Upgrade)
Pfizer's stock has hit bottom and could see a boost from bird flu fears. Covid-related sales now account for less than 15% of Pfizer's total revenues, de-risking the investment story. Pfizer is cutting $4 billion in annual costs and has raised its EPS target for the year.
How Much Will Pfizer Pay Out in Dividends This Year?
Pfizer sells more innovative new medicines than any of its peers. Pfizer has raised its dividend payout every year since 2009.
1 No-Brainer Dividend Stock Yielding More Than 5% to Buy and Hold Forever
Pfizer's revenue and net income are moving in the wrong direction. However, the drugmaker has been rejuvenating its pipeline.
Pfizer: Down To A Historically Low Valuation - Is It A Buy?
Pfizer stock is at its lowest price in over 11 years, presenting a potential buying opportunity. The company's valuation is near historically low levels, and consensus analysts expect earnings to stabilize. The structure of price on the chart suggests that Pfizer may see a bounce and potentially reach the $36-$44 range.
3 Stocks That Can Help You to Get Richer in 2025 and Beyond
Pfizer's recent slump is understandable and not likely a long-term issue. Veeva Systems has a lot to offer its 1,400-plus customers, and they tend to stick around.
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
